We are live on ! Find out more
WGS icon

GeneDx Holdings

85.27 USD
+1.31
1.56%
At close Updated Sep 11, 4:00 PM EDT
Pre-market
After hours
85.00
-0.27
0.32%
1 day
1.56%
5 days
-2.86%
1 month
4.32%
3 months
39.81%
6 months
0.2%
Year to date
-35.55%
1 year
-32.27%
5 years
-70.5%
10 years
-73.63%
 

About: GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Employees: 1,300

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 1.9%
Neutral 97.4%
Negative 0.6%
Neutral
Business Wire
3 days ago
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Positive
Zacks Investment Research
4 days ago
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
3 Promising Genomics Stocks in the Spotlight in 2026
Neutral
Business Wire
11 days ago
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Positive
Benzinga
17 days ago
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Neutral
Business Wire
19 days ago
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
Positive
Zacks Investment Research
24 days ago
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Positive
Seeking Alpha
25 days ago
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx: Why I Think The Worst Is Behind The Business
Neutral
Business Wire
1 month ago
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
Neutral
Business Wire
1 month ago
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the Canaccord Genuity and Wells Fargo investor conferences.
GeneDx to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
1 month ago
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Nebius Group, Credo Technology Group, and Guardant Health, Inc. were among the top contributors to performance. During the quarter, Credo shares contributed positively to performance as investors responded favorably to the company's rapid revenue growth and rising demand from hyperscale customers. Karman Holdings Inc., GeneDx Holdings Corp., and Forte Biosciences Inc. were among the top detractors from performance.
Alger Small Cap Focus Fund Q2 2026 Portfolio Review
Price charts implemented using Lightweight Charts™